Eur Rev Med Pharmacol Sci 2014; 18 (13): 1896-1903

Inositol: history of an effective therapy for Polycystic Ovary Syndrome

M. Bizzarri, G. Carlomagno

Department of Experimental Medicine, “Sapienza” University of Rome, Rome, Italy. g.carlomagno@lolipharma.it


Inositol is a physiological compound belonging to the sugar family. The two inositol stereoisomers, myo-inositol and D-chiroinositol are the two main stereisomers present in our body.

Myo-inositol is the precursor of inositol triphosphate, a second messenger regulating many hormones such as TSH, FSH and insulin. D-chiroinositol is synthetized by an insulin dependent epimerase that converts myo-inositol into D-chiro-inositol. Polycistic Ovary Syndrome (PCOS) is a metabolic and hormonal disorder and a common cause of infertility. Insulin resistance and the consequent hyperinsulinaemia contribute to hyperandrogenism development, typical marker of PCOS. In these patients myo and/or D-chiro-inositol administration improves insulin sensivity while only myo-inositol is a quality marker for oocytes evaluation.

Myo-inositol produces second messengers for FSH and glucose uptake, while D-chiroinositol provides second messengers promoting glucose uptake and glycogen synthesis. The physiological ratio of these two isomers is 40:1 (MI/DCI) and seems to be an optimal approach for the treatment of PCOS disorders.

Free PDF Download

To cite this article

M. Bizzarri, G. Carlomagno
Inositol: history of an effective therapy for Polycystic Ovary Syndrome

Eur Rev Med Pharmacol Sci
Year: 2014
Vol. 18 - N. 13
Pages: 1896-1903